IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

IXICO plc

IXICO is a precision analytics company delivering intelligent insights in neuroscience, supporting biopharmaceutical companies across all phases of CNS clinical research.

IXICO

IT Services and IT Consulting

TrialTracker™

IXICO | 12,355 followers on LinkedIn. Experts in end-to-end management and analysis of neuroimaging clinical trials powered by expertise &amp; AI. | Advancing medicine and human health by transforming data into clinically meaningful insights.

IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights.

Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

Mark Warne

CEO | Non-Executive Board Director

Bram Goorden

Vice President Imaging at IXICO

Michelle Lax

Chief Scientific Officer at IXICO

Robin Wolz

Neuroimaging, bringing together data from various platforms and technologies presents a significant challenge. Our upcoming webinar addresses this crucial issue, offering a comprehensive solution to enhance imaging processes and improve data consistency. Join us as we explore the complexities of imaging harmonization, guided by industry experts who will share their professional insights and strategies. This webinar will cover: ➡️Understanding the fundamental challenges of imaging harmonisation. ➡️Exploring innovative solutions to integrate diverse imaging data. ➡️Learning best practices for maintaining data integrity and accuracy ➡️Gaining insights into the latest technological advancements in imaging. Register here: https://lnkd.in/e5dXSUiJ Don't miss this opportunity to engage with our experts, gain valuable insights, and have your questions answered. Register now to secure your spot and take a step towards mastering the complexities of imaging harmonisation. Webinar Details: 📅 Date: December 3rd, 2024 🕓 Time: 3pm GMT / 4pm CET / 10am EST 🎙️ Speakers: ➡️ Niccolo Fuin , Senior Biomarker Scientist - IXICO ➡️ Helen Crawford , Head of Image Management - IXICO If you have questions about the upcoming webinar that you want us to think about answering, let us know by replying to this email. If you can't make it to the webinar but want the recording, register anyway so we can send it to your inbox after the webinar has concluded. Lastly, please forward this to someone you think might benefit from this webinar. We look forward to seeing you then!

Tomorrow, we'll be at the International Congress for Ataxia Research (ICAR) 2024 hosted by Ataxia UK , National Ataxia Foundation , Friedreich's Ataxia Research Alliance (FARA) ’s, and Ataxia Global Initiative (AGI) in London, United Kingdom A recap of our time at ICAR: Kirsi Kinnunen will present our latest research in the field of Ataxia research: 🕛Tuesday 12 November 6:10pm-7:30pm GMT - Poster Session 1 🧠 Poster Presentation "Diffusion MRI analyses of infratentorial regions in Friedreich’s ataxia" If you're about tomorrow - drop us a message so we can meet! See you in London tomorrow!

In the rapidly evolving field of neuroimaging, harmonising data across diverse platforms and technologies presents a significant challenge. Our upcoming webinar addresses this critical issue, offering a comprehensive solution to streamline imaging processes and enhance data consistency. Join us as we delve into the complexities of imaging harmonisation, guided by our experts who will share their insights and strategies that will help you make the complex, understandable. Webinar Details: 📅 Date: December 3rd, 2024 🕓 Time: 3pm GMT / 4pm CET / 10am EST 🎙️ Speakers: 🧠 Niccolo Fuin , Senior Biomarker Scientist - IXICO 🧠 Helen Crawford , Head of Image Management - IXICO Register Here: https://lnkd.in/e5dXSUiJ Our webinar will cover: ▶️ Understanding the fundamental challenges of imaging harmonisation. ▶️ Exploring innovative solutions to integrate diverse imaging data. ▶️ Learning best practices for maintaining data integrity and accuracy ▶️ Gaining insights into the latest technological advancements in imaging. Don't miss this opportunity to engage with our experts, gain valuable insights, and have your questions answered. If you have questions about the upcoming webinar that you want us to think about answering, let us know by dropping us a message If you can't make it to the webinar but want the recording, register anyway so we can send it to your inbox after the webinar has concluded. Lastly, please forward this to someone you think might benefit from this webinar. See you December 3rd!

Our CEO Bram Goorden discusses IXICO's strategic vision and the exciting opportunities ahead following the company's recent successful fundraise in a recent interview with Paul Hill , from Vox Markets . Bram highlighted IXICO's commitment to leveraging advanced AI and data analytics to drive innovation in neurological research. He emphasized the importance of expanding our global capabilities in neuroimaging to support the development of groundbreaking therapies for conditions like Alzheimer’s, Parkinson’s, and Huntington’s disease. Bram also shared his enthusiasm for fostering a culture of collaboration and excellence within IXICO, ensuring we continue to deliver top-tier services to our clients in the biopharmaceutical industry. The future is bright for research in neurodegenerative disease and IXICO aims to play an increasing role in the space! ▶️ Watch the video here: https://lnkd.in/ed9b6F6V

Join us next week in London, United Kingdom for the International Congress for Ataxia Research 2024 hosted by Ataxia UK , National Ataxia Foundation , Friedreich’s Ataxia Research Alliance (FARA), and Ataxia Global Initiative (AGI) Kirsi Kinnunen will present our latest research in the field of Ataxia research: 🕛Tuesday 12 November 6:10pm-7:30pm GMT - Poster Session 1 🧠 Poster Presentation "Diffusion MRI analyses of infratentorial regions in Friedreich’s ataxia" Kirsi will be speaking with the community about the latest developments in imaging biomarkers for Ataxia research, so if you're about - drop us a message if you're going so we can arrange a meeting! See you in London!

Nuanced screening scenarios for patients enrolling in AD clinical trials will be key to understanding disease progression and maximising the insight gained from the trial. Robin Wolz talks about the findings of our work at CTAD Clinical Trials on Alzheimer's Disease this week and the depth of knowledge gained from the Global Alzheimer's Platform Foundation Bio-Hermes Trial. Our CEO, Bram Goorden comments: "The excitement at this edition of CTAD is palpable with important reads-outs, including our own further Bio-Hermes analyses, but it is also clear that we will see many new AD programs starting in the near future. I look forward to IXICO playing a major role in assisting these efforts as we have enabled our platform to support the latest imaging biomarker requirements. Alzheimer’s research and development for patients is thriving!” To find out more about our work in utilising imaging biomarkers to support patient stratification, safety, and efficacy reporting, view the latest publications that we've presented over 2024: https://lnkd.in/dUd5nnT And if you're interested in learning more about Robin's presentation - drop us a message.

#IXI – the brains behind brain scans Know anyone who’s suffering from Alzheimer's (AD), Parkinson's (PD) &/or Huntington’s (HD)? These neurological conditions tragically affect 10ms of people worldwide. Luckily there’s help on its way. You see after several false starts, two Alzheimer's drugs were approved last year. Both treatments slow a patient’s cognitive decline, but require regular brain scans to monitor possible side-effects. These successes however have triggered an avalanche of new neurological research, reflecting the enormous unmet need. Here new clinical studies are being conducted on next generation therapeutics. Most of which also need MRIs in order to assess a drug’s safety, efficacy & longitudinal performance, as well as to assist in patient trial selection. This is where IXICO (Mrkcap £9m) fits in. It is one of the world’s leaders in the highly specialised assessment of brain scans. Helping BigPharma & CROs develop new drugs right from the test-tube, through to commercial launch (see charts) & post marketing surveillance. The firm is currently running 26 trials for 18 customers. Here its cutting edge science, industry experts & AI algorithms can detect & interpret >150 unique brain structures & digital biomarkers with microscopic precision. In fact, its highly contextualised database, incorporating a vast repository of 250k images, acts as a major competitive moat. All the information is securely stored too for the client within IXICO’s end-to-end TrialTracker software platform. Thus improving efficiency, speed, regulatory submissions and quality of decision making. Sure the past 2-3 years has been tough across the whole sector, as many Biotechs have dialled back investment. Yet equally this is changing, with the Board aiming to almost double turnover to £10m over the next 3-4 years vs an est £5.5m for Sept FY24. Breakeven sales is c.£8m. Whilst the orderbook stood at a healthy £15.1m on 31 Aug’24 vs £12.7m Mar'24. This strong growth will be achieved by leveraging its renowned HD expertise (£12m TAM) to penetrate further into the much larger research pools of AD (£30m) & PD (£15m). Alongside expanding more into the US and incorporating new digital biomarkers into the imaging platform. All funded after the recent over-subscribed £4.05m placing at 9.5p. Lastly wrt the numbers, house broker Cavendish have a 24p/share price target, based on Sept FY’25 sales & EBITDA coming in at £6.0m & -£1.4m respectively. Plus at 9.5p, the stock trades on <1x EV/revs, which looks far too cheap. CEO Bram Goorden – who joined in the summer & has been pivotal in driving IXICO ’s expansion strategy - commented: "The fundraising will accelerate the growth & commercial reach of our AI driven technology platform.” Similarly, CSO Robin Wolz has been invited to present at several prominent industry events. An encouraging sign of the increasing importance of #IXI 's specialist imaging services. Disclosure: IXICO is a Vox Markets client

Paul Hill

We've had a fantastic few days at CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain! Thank you to everyone that's spoken with Robin Wolz , Bram Goorden and Roxanne Langlois during the conference, we are still around so if you have a moment, please do say hello! Here's a photo of Robin as he delivers his presentation titled: "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" where we hope insights from the Global Alzheimer's Platform Foundation Bio-Hermes Trial will help inform the AD clinical research community. 🎃Enjoy the spooky festivities today, and if you're at CTAD, we hope to see see you there 🎃

Next week, we are at CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain from Oct 29th to Nov 1st! Here's a recap of our presence: Robin Wolz will present our latest findings with the Global Alzheimer's Platform Foundation on the Bio-Hermes Trial. 🕛Thursday, October 31st 2024 at 2:35pm in OC26 🧠 Oral Communication "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" If you're at CTAD, Bram Goorden and Roxanne Langlois will be with Robin to discuss and share imaging biomarker insights with the AD research community. Drop us a message if you're going so we can arrange a meeting! See you in Madrid!

Innovative trial recruitment strategies are crucial as it’s estimated that by 2050, 153 million people will live with dementia. Our deep-learning framework for clinical trial enrichment in Alzheimer’s Disease enhances trial enrichment using neuroimaging and clinical/demographic variables, designed to handle missing inputs effectively. 🧠 We utilized T1-MR and amyloid-PET images from major repositories and trained advanced neural networks and classifiers. This approach has shown promising results in identifying participants at early disease stages with accelerated decline. Our framework achieved high accuracy and can significantly reduce PET imaging costs. To learn more about our methods and results, download the full poster 📄 https://lnkd.in/e9mRMRXW

IXI

COM:IXICO

IXICO

Last Close

12.75

25/11 09:20

Market Cap

33.85K

Beta: -

Volume Today

75K

Avg: -